Please assess the completion status of the following clinical trial:

Trial Title: Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Patients \>= 18 years of age with histologically or cytologically-confirmed stage IV NSCLC, and a confirmed EGFR mutation status in case of non-squamous cell histology~   * Stratum 1: Non-squamous NSCLC without activating EGFR mutation~  * Stratum 2: Squamous NSCLC~  * Stratum 3: Non-squamous NSCLC harboring an activating EGFR mutation~2. PR or SD according to RECIST Version 1.1 after first-line therapy which should have consisted of:~   * Stratum 1: PR or SD after cisplatin or carboplatin and pemetrexed treatment (at least 4 cycles)~  * Stratum 2: PR or SD after cisplatin or carboplatin and a non-platinum compound treatment (at least 4 cycles)~  * Stratum 3: PR after up to 6 months or SD after at least 3 and up to 6 months of gefitinib or erlotinib treatment~3. For patients in stratum 1, maintenance therapy with pemetrexed should be indicated as to the investigator's opinion~4. Presence of at least one tumor lesion that is eligible for radiation with 4 x 5 GY, and at least one additional measurable tumor lesion according to RECIST Version 1.1.~   Tumor lesions eligible for radiation are:~  * Bone metastases~  * Lymph nodes in the paraclavicular, axillary or cervical regions~  * Skin or subcutaneous metastases~  * For patients in strata 1 and 2 only: Thoracic lesions (centrally located lung tumor, lymph nodes in the lung hilus or mediastinum)~5. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0 to 1~Key Exclusion Criteria:~1. Previous active immunotherapy for NSCLC (including vaccination, therapy with anti-CTLA4 antibodies)~2. Estimated life expectancy ≤ 3 months~3. Need for immunosuppressive treatment including daily systemic steroid doses of ≥ 10 mg prednisone equivalent per day~4. Active skin disease (e.g. atopic dermatitis) in the areas for vaccine injection (upper arms or thighs) not allowing intradermal injections into areas of healthy skin~5. Concurrent or planned major surgery~6. Prior splenectomy or prior allogeneic bone marrow transplantation~7. History of pneumonitis~8. Documented history or active autoimmune disorders with the exception of vitiligo, diabetes mellitus type 1 or autoimmune thyroiditis requiring hormone replacement only~9. Primary or secondary immune deficiency~10. Allergies to any components of the study drug including allergy to protamine hydrochloride (e.g. allergy to protamine-containing insulin) or fish allergy~11. Seropositive for HIV, HBV, HCV or any other infection requiring anti-infection therapy~12. For patients in stratum 3: persisting \>= grade 3 skin rash at time of enrollment~13. Known brain metastases with the exception of stable metastases being treated with stereotactic radiation or surgery)~    \*\*Local German Amendment: 13. Brain metastases (symptomatic or asymptomatic) or leptomeningeal involvement~14. Uncontrolled medical condition considered as high risk for the treatment with an investigational drug (e.g. unstable diabetes mellitus, vena-cava-syndrome, uncontrolled pleural effusion, pericardial effusion, symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable angina pectoris/myocardial infarction within the previous 6 months, significant cardiac arrhythmia, history of stroke or transient ischemic attack within the previous 6 months, severe hypertension according to WHO criteria, and uncontrolled systolic blood pressure ≥ 180 mmHg at the time of enrollment~15. For patients planned to undergo radiation of thoracic lesions: inadequate lung function dependent on the intended tumor volume and location to be irradiated (to be assessed by the radio oncologist)~16. History of encephalitis or multiple sclerosis~17. Active inflammatory conditions such as inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CV9202 and local radiation (Type: EXPERIMENTAL): CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues